Department of Urology

Medicine and Dentistry

1. Patient 100%
2. Inpatient 68%
3. Gallium 68 59%
4. Prostate Cancer 44%
5. Ligand 39%
6. Positron Emission Tomography 37%
7. Biological Marker 31%
8. Prostate Specific Membrane Antigen 30%
9. Prostatectomy 26%
10. Non Muscle Invasive Bladder Cancer 25%
11. Diagnosis 25%
12. Recurrent Disease 23%
13. Assessment 23%
14. Neoplasm 22%
15. Cystectomy 19%
16. Metastatic Carcinoma 18%
17. Bladder Cancer 17%
18. Lymph Node Metastasis 17%
19. Therapeutic Procedure 17%
20. Association 17%
21. Magnetic Resonance Imaging 16%
22. PET-CT 16%
23. Tissues 16%
24. Castration Resistant Prostate Cancer 15%
25. Lymphocyte 15%
26. Stone 15%
27. Neutrophil 15%
28. Development 15%
29. Mortality 15%
30. Systemic Therapy 15%
31. Peroperative Complication 15%
32. Surgery 14%
33. Combination Therapy 13%
34. Survival 13%
35. Biochemical Recurrence 12%
36. Urinary Diversion 12%
37. Transitional Cell Carcinoma 11%
38. Analysis 11%
39. Urology 11%
40. Age 11%
41. Lymph Node 11%
42. Decision Making 11%
43. Overall Survival 11%
44. PET-MRI 10%
45. Complication 10%
46. Radiation Therapy 9%
47. Hormone 9%
48. Stent 9%
49. Muscle Invasive Bladder Cancer 9%
50. Body Mass Index 9%
51. Radioactive Tracer 9%
52. Accuracy 8%
53. Histology 8%
54. Hospital Management 8%
55. Man 8%
56. Prostate Specific Antigen 8%
57. Recurrence Free Survival 8%
58. Germinoma 7%
59. Woman 7%
60. Lymphocyte Antigen Receptor 7%
61. Antigen 7%
62. Protein Expression 7%
63. Cystoscopy 7%
64. Radioligand 7%
65. Seasonal Variation 7%
66. Cancer Prognosis 7%
67. Diet 7%
68. Nephroureterectomy 7%
69. Clinical Significance 7%
70. Patient Selection 7%
71. Ureter Stone 7%
72. Cancer Registry 7%
73. Meta-Analysis 7%
74. Systematic Review 7%
75. Monocyte 7%
76. Lutetium 177 7%
77. Gallium 7%
78. Cytoreductive Surgery 7%
79. Joint 7%
80. Diagnostic Performance 7%
81. Pain 7%
82. Biodistribution 7%
83. Androgen Deprivation Therapy 7%
84. DNA 7%
85. Cells 7%
86. Overactive Bladder 7%
87. Circulating Tumor DNA 7%
88. Cross Sectional Study 7%
89. Diseases 7%
90. Lesion 7%
91. Follow up 6%
92. Risk Stratification 6%
93. Morphology 5%
94. Proportional Hazards Model 5%
95. Nephrostomy 5%
96. Response Evaluation Criteria in Solid Tumors 5%
97. Predictor 5%
98. Logistic Regression Analysis 5%
99. Evaluation Study 5%